Q4 2024 Earnings Call Transcript February 12, 2025 Operator: Good morning. My name is Jennifer and I will be your conference ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Biogen Inc (BIIB) reports a 17% increase in Q4 EPS, driven by new product launches, despite facing revenue declines and competitive pressures.

We think Biogen's neurology, immunology, and focus on rare diseases support a narrow moat. Biogen's strategy has its roots in the 2003 merger of Biogen (Avonex for treating multiple sclerosis, or MS) ...

Christopher Viehbacher; President, Chief Executive Officer, Director; Biogen Inc Priya Singhal; Executive Vice President - Head of Development; Biogen Inc Michael McDonnell; Chief Financial Officer, ...

Robin Swartz, the Chief Operating Officer and Chief Business Officer of Voyager Therapeutics, Inc. (NASDAQ:VYGR), recently sold 6,950 shares of the company's common stock. The sale comes as the stock ...

The annual event, held Dec. 6, 2024, at the JW Marriott Tampa Water Street, raised funds for the Friedreich’s Ataxia Research ...

The company is expecting 2025 EPS to range from $15.25 to $16.25, below the $16.33 FactSet consensus. Revenue is expected to decline by a mid-single-digit percent on a constant currency basis, as ...

While the continued erosion of Biogen’s multiple sclerosis franchise and weaker-than-expected 2025 guidance doesn’t seem to ...

Biogen Inc. CEO Christopher Viehbacher gave investors an overview of what type of deals the company is looking for Wednesday ...

Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis ...